Information  X 
Enter a valid email address

Synairgen announces research collaboration

By BFN News | 07:33 AM | Wednesday 05 August, 2015

Synairgen and Australian pharmaceutical company Pharmaxis Ltd have entered into a research collaboration to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF). IPF affects in the region of 100,000 people in the US. Current products are expected to produce global revenues in excess of $1.1 billion by 2017. The LOXL2 enzyme is being targeted because it is known to promote scar tissue which hardens and irreparably damages the lungs of IPF patients. It is hoped that the inhibition of LOXL2 will slow the build-up of scar tissue and improve survival rates that are worse than for many cancers. Story provided by

a d v e r t i s e m e n t